United States · 
What does The Column Group invest in?
The Column Group invests most often at Series A and Series B (73% of the rounds on record), in sectors such as Life Sciences.
The Column Group highlights
- 01
1 cheques in the last 12 months
- 02
Mostly Series A and Series B: 73% of its rounds
- 03
Sole investor in 4 rounds, median $24M
- 04
3 exits from the portfolio
What they do
The Column Group (TCG) is a venture ecosystem dedicated to fueling scientific innovation in the life sciences industry.From their own website
- Type
- VC firm (from a list, unverified)
- Cheque size
- $100K – $5.0M as they say
- Stages
- SeedSeries ASeries BGrowthPre-IPO
- Sectors
- Life Sciences
- Based in
- San Francisco, United States
- Cold pitches
- Not stated
The record
Every round we can evidence, newest first46 appearances
- 2026
1 round
- Oct
- 2019
4 rounds
- Nov
- Oct
- Oct
- Jul
- 2018
7 rounds
- Dec
- May
- May
- Apr
- Feb
- Feb
- Jan
- 2017
4 rounds
- Dec
- Sept
- Jul
- Feb
- 2016
1 round
- Dec
- 2015
3 rounds
- Dec
- Dec
- Oct
- 2014
3 rounds
- Dec
- May
- Jan
- 2013
1 round
- Oct
- 2012
5 rounds
- Oct
- Oct
- Jul
- Jun
- May
- 2011
3 rounds
- Jul
- Jun
- Jun
- 2010
4 rounds
- Jul
- Jun
- Jun
- Apr
- 2009
7 rounds
- Dec
- Dec
- Dec
- Aug
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
Named by the firm itself, on a filing, its Form ADV or its company registration14 named
DVDavid Van Norman GoeddelManaging Member of the General Partner of the General PartneriFiling they signed
DVDavid V. Goeddel, Ph.D.Managing Partner of The Column Group II GP, LP, the general partneriFiling they signed
DVDavid V Goeddel Ph DExecutive OfficeriFiling they signed
DVDavid V. Goeddel, PHDManaging Member of the General Partner of the General PartneriFiling they signed
HEHarald EkmanManaging Partner of The Column Group II GP, LP, the general partneriFiling they signed
JPJames Philip EvangelistaChief Financial OfficeriForm ADV
LVLaurence V. Lasky, Ph.D.Executive OfficeriFiling they signed
MPMagnus Persson, M.D., Ph.D.Managing Partner of The Column Group II GP, LP, the general partneriFiling they signed
PHPeter Haqvin Erland SvennilsonManaging Partner of The Column Group II GP, LP, the general partneriFiling they signed
RKRichard Klausner, M.D.Managing Partner of The Column Group II GP, LP, the general partneriFiling they signed
TVTim V KutzkeyManaging Member of the General Partner of the General PartneriFiling they signed
TVTim V. Kutzkey, PHDManaging Member of the General Partner of the General PartneriFiling they signed
TVTim V. Kutzkey, Ph.D.Executive OfficeriFiling they signed
TWTimothy William KutzkeyManaging PartneriForm ADV
We also hold 23 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
What the register says
From the firm's own filings with the SEC, which it must file accurately by law
$3.3Bgross assets of its fundsOct 2026
Exemptreporting adviserventure or small private funds
- Legal name
- The Column Group Management LP
- SEC number
- CRD 161912
What they claim to have backed
From their own portfolio page (on their website)
10 of 29 we have independently watched raise
Thumbnail for A2 BiotherapeuticsThumbnail for Arcus BiosciencesThumbnail for Circle PharmaThumbnail for KallyopeThumbnail for Oric PharmaceuticalsThumbnail for Peloton TherapeuticsThumbnail for PlexiumThumbnail for Revolution MedicinesThumbnail for SurrozenThumbnail for Tenaya TherapeuticsNovartisThumbnail for Aragon PharmaceuticalsThumbnail for Atavistik BioThumbnail for Carmot TherapeuticsThumbnail for Escient PharmaceuticalsThumbnail for Gritstone BioThumbnail for Hexagon BioThumbnail for Immune DesignThumbnail for Judo BioThumbnail for Lyterian TherapeuticsThumbnail for Neurona TherapeuticsThumbnail for Ngm BioThumbnail for Nura BioThumbnail for Rapt TherapeuticsThumbnail for Seragon PharmaceuticalsThumbnail for SyntheXThumbnail for SynthekineThumbnail for Tortugas NeuroscienceThumbnail for Tr1x Bio
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.
Exits from the portfolio
Companies it backed that were later bought or listed3 in all
Flexus BiosciencesBought by Bristol-Myers Squibb$1.3BFeb 2015
PTC TherapeuticsListed$125MJun 2013
Aragon PharmaceuticalsBought by Johnson & Johnson$1.0BJun 2013
An exit counts when it came after the firm's first round in the company. From historical deal records.